Evidence map›Paper›PMID 27818949›Full record

ArticleFrontiers in oncology2016

The Necrosis-Avid Small Molecule HQ4-DTPA as a Multimodal Imaging Agent for Monitoring Radiation Therapy-Induced Tumor Cell Death.

Marieke A Stammes, Azusa Maeda, Jiachuan Bu, Deborah A Scollard, Iris Kulbatski, Philip J Medeiros, Riccardo Sinisi, Elena A Dubikovskaya, Thomas J A Snoeks, Ermond R van Beek and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Necrosis binding of Ac-LysEJNMMI research · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Review of quantitative multiscale imaging of breast cancer.Journal of medical imaging (Bellingham, Wash.) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Marieke A StammesDepartment of Radiology, Leiden University Medical Center, Leiden, Netherlands; Percuros BV, Enschede, Netherlands.
Azusa MaedaPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Jiachuan BuPrincess Margaret Cancer Center, University Health Network , Toronto, ON , Canada.
Deborah A ScollardSTTARR Innovation Centre, University Health Network , Toronto, ON , Canada.
Iris KulbatskiPrincess Margaret Cancer Center, University Health Network , Toronto, ON , Canada.
Philip J MedeirosPrincess Margaret Cancer Center, University Health Network , Toronto, ON , Canada.
Riccardo SinisiLCBIM, Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne (EPFL) , Lausanne , Switzerland.
Elena A DubikovskayaLCBIM, Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne (EPFL) , Lausanne , Switzerland.
Thomas J A SnoeksDepartment of Radiology, Leiden University Medical Center , Leiden , Netherlands.
Ermond R van BeekDepartment of Radiology, Leiden University Medical Center , Leiden , Netherlands.
Alan B ChanPercuros BV , Enschede , Netherlands.
Clemens W G M LöwikDepartment of Radiology, Erasmus Medical Center , Rotterdam , Netherlands.
Ralph S DaCostaPrincess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Techna Institute, University Health Network, Toronto, ON, Canada.
Leiden University Medical Center · NLPrincess Margaret Cancer Centre · CAUniversity Health Network · CAÉcole Polytechnique Fédérale de Lausanne · CHErasmus MC · NLPercuros (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMost effective antitumor therapies induce tumor cell death. Non-invasive, rapid and accurate quantitative imaging of cell death is essential for monitoring early response to antitumor therapies. To facilitate this, we previously developed a biocompatible necrosis-avid near-infrared fluorescence (NIRF) imaging probe, HQ4, which was radiolabeled with MATERIALS AND

methodsRadiation-induced tumor cell death was examined in a xenograft mouse model of human breast cancer (MCF-7). Tumors were irradiated with three fractions of 9 Gy each. HQ4-DTPA was injected intravenously after the last irradiation, NIRF and photoacoustic imaging of the tumors were performed at 12, 20, and 40 h after injection. Changes in probe accumulation in the tumors were measured

results

conclusionHQ4-DTPA has high specificity for dead cells

Indexed as

cancercell deathcyaninefluorescence imagingmultimodal imagingnecrosis avid contrast agentradiation therapytreatment response

Identifiers

PMID27818949
PMCPMC5073092
OpenAlexW2537779812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.